KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to -$3.4 million.

  • Emergent BioSolutions' Cash from Investing Activities fell 10303.57% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.9 million, marking a year-over-year increase of 1960.09%. This contributed to the annual value of $125.2 million for FY2024, which is 4102.68% down from last year.
  • Emergent BioSolutions' Cash from Investing Activities amounted to -$3.4 million in Q3 2025, which was down 10303.57% from $17.2 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Cash from Investing Activities high stood at $257.7 million for Q2 2023, and its period low was -$271.6 million during Q3 2022.
  • For the 5-year period, Emergent BioSolutions' Cash from Investing Activities averaged around -$10.2 million, with its median value being -$15.1 million (2023).
  • As far as peak fluctuations go, Emergent BioSolutions' Cash from Investing Activities tumbled by 39202.9% in 2022, and later surged by 90280.37% in 2023.
  • Emergent BioSolutions' Cash from Investing Activities (Quarter) stood at -$45.8 million in 2021, then grew by 0.87% to -$45.4 million in 2022, then surged by 74.89% to -$11.4 million in 2023, then soared by 350.88% to $28.6 million in 2024, then tumbled by 111.89% to -$3.4 million in 2025.
  • Its last three reported values are -$3.4 million in Q3 2025, $17.2 million for Q2 2025, and $59.5 million during Q1 2025.